Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AES-trial in Niger for shortened multidrug-resistant tuberculosis treatment
PACTR202505593072442Not yet recruiting
- Sponsor
- Damian Foundation Niger
- Start
- Apr 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of bedaquiline, pretomanid, linezolid, moxifloxacin and levofloxacin in Tuberculosis (TB) (2 arms), sponsored by Damian Foundation Niger. Primary endpoint: Safety comparison between modified 5-month regimen and BPaLM. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
bedaquilinepretomanidlinezolidmoxifloxacinlevofloxacin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202505593072442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202505593072442.